New warning for Rocephin
Labeling for Roche's Rocephin (ceftriaxone) has been strengthened to warn against concomitant use with calcium-containing solutions or products in newborns based on adverse events reported during postmarketing clinical use of the anti-infective. Isolated neonatal deaths were associated with calcium-ceftriaxone precipitates in the lungs and kidneys, according to a "Dear Doctor" letter sent in June. Labeling also has been reinforced to contraindicate against use in hyperbilirubinemic neonates...
You may also be interested in...
Three new directors at Tenax Therapeutics, and a flurry of CMO and CFO appointments.
US firm 180 Life Sciences believes that existing anti-TNF biologics have the potential to address a variety of other conditions in which patients currently have unmet needs. CEO Dr Jim Woody tells Generics Bulletin about how the company is exploring new indications for off-patent biologics.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, including Lumoxiti, AstraZeneca's drug for hairy cell leukemia. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).